Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams.

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Case Western University scientists were gifted $2.5 million to advance MS research into whether glial cells can be targeted to repair myelin.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

This week — and every week — we celebrate our nurse practitioners for their dedication, expertise, and heart. Thank you for ...

New bilingual database allows patients to search by cancer type, contains details about eligibility, treatment, location and ...

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Robert Harshbarger Jr. pleaded guilty in 2013 to health care fraud and distributing a misbranded drug. His wife, Diana ...